Dig Dis Sci: Moderate to severe ulcerative colitis patients who try to use inflixi monoantigen on behalf of 5-amino-salicylicate treatment will not be effective

Ulcerative colitis (UC) is characterized by disease activity and remission of alternating episodes, and UC's therapeutic goal is to induce and maintain disease relief and prevent complications by introducing highly effective therapeutic drugs in the early stages of the disease, and for mild to moderate UC, current literature and guidelines support the use of 5 First-line treatment of amino saliolic acid (5-ASA) to induce and maintain remission, but despite 5-ASA treatment, some patients are progressing to moderate to severe UC and need to be upgraded to biologics or small molecule therapy.
biologics: Anti-tumor necrosis factor-α (anti-TNF) therapy is powerful in patients who induce and maintain the ineffectiveness of 5-ASA therapy.
, however, it is not clear whether 5-ASA should be discontinued or continued in patients upgraded to anti-TNF therapy.
, this study aims to assess the effects of accompanying 5-ASA therapy on clinical outcomes in patients with ulcerative colitis (UC) who are gradually upgraded to Invlixi mono-resistant.
a retrospective study, the researchers reviewed the clinical conditions of moderate to severe UC patients who began using Invlixi monoantigen therapy at the University of Alberta between January 2012 and December 2017.
the main observations were the degree of clinical remission at 6 and 12 months (partial Mayo score .lt;2).
secondary observations include endoscopy (endoscopic Mayo -lt;2) and deep remission (clinical and endoscopy combined remission), hospitalization or colonectomy.
single-factor and multiple logical regression models are used to estimate the advantage ratio of results and 95% CI.
followed 112 patients over an average 47-month follow-up period.
the proportion of patients using 5-ASA using immunomodulants at the same time (73.3% VS 54.1%, p s 0.03).
no difference in clinical remission rates at 6 months (aOR 2.59, p s 0.07) or 12 months (aOR 0.43, p s 0.06).
at 12 months, patients who received 5-ASA at the same time were less likely to achieve endoscopic remission (aOR 0.08, p s 0.01) and deep remission (aOR 0.07, p s 0.02).
differences in adverse outcomes between the two groups, such as need for emergency treatment, hospitalization and colonectomy.
, this study confirms that moderate to severe UC patients who have been upgraded to inflixi monoantimmune therapy can stop 5-ASA because it has no additional benefits in controlling inflammation.